期刊文献+

ki67和cyclin D_1在肾癌组织中的表达及其临床意义 被引量:3

The expression and clinical significance of ki67 and cyclin D_1 in renal cell carcinoma
下载PDF
导出
摘要 目的:探讨ki67和cyclin D1在肾细胞癌(RCC)组织中的表达及意义。方法:利用免疫组化方法检测ki67和cyclin D1在50例RCC组织中的表达情况。50例的病理分级G111例,G230例,G39例;TNM分期Ⅰ期24例,Ⅱ期16例,Ⅲ期5例,Ⅳ期5例。结果:RCC组织中ki67标记指数为(14.0±10.95)%,cyclin D1的阳性率为80%;ki67在RCC病理分级G1与G3,G2与G3之间表达差异显著,在Ⅰ期与Ⅲ期、Ⅳ期之间表达差异显著,Ⅱ期与Ⅲ期、Ⅳ期之间表达亦差异显著,ki67和cyclinD1在RCC及正常肾组织中的表达差异有统计学意义(均P<0.05)。结论:ki67和cyclinD1在RCC组织中存在着高表达,RCC组织中ki67标记指数随着病理分级和临床分期的增高而增高,与肿瘤的生物学行为有一定关系。 Objective:To investigate the expression of ki67, cyclin D1 in renal cell carcinoma(RCC) and its clinical significance. Methods:The expression of ki67 and cylcin D1 was examined in 50 cases of RCC immunohistochemically (35 males and 15 females, 28 left and 22 right, mean age 54.1 years, range from 31 to 79 years). The nuclear grade was G1 in 11, G2 in 30, G3 in 9. The clinical stage was Ⅰ in 24, Ⅱ in 16,Ⅲ in 5,Ⅳ in 5. The histological cell types of these tumors were clear cell in 34 specimens, papillary in 7 specimens and granular cell in 7 specimens. Ten normal kidney specimens had been detected. Results:The ki67 labeling index of ki67 expression in RCC was 14.0% ±10.95%. The positive rates of cyclin D1 expression in RCC was 80%. There was significant correlation between ki67 expression and histological grade or clinical stage (G1 and G3, G2 and G3,Ⅰ and Ⅲ, Ⅰand Ⅳ, Ⅱ and Ⅲ, Ⅱ and Ⅳ) ( P〈0.05). There was significant correlation between ki67,cyclin D1 in RCC and normal kidney ( P 〈0.05). Conclusions: Ki67 and cyclinD1 were highly expressed in RCC. High Ki67 labeling index correlated with high grade and stage.
出处 《临床泌尿外科杂志》 2008年第3期219-221,227,共4页 Journal of Clinical Urology
关键词 肾肿瘤 肿瘤标志物 免疫组织化学 Renal cell carcinoma ki67 CyclinD1 Immunohistochemistry Prognosis
  • 相关文献

参考文献3

二级参考文献17

共引文献82

同被引文献44

  • 1聂明豪,杜明,李秀荣.细胞角蛋白19及Ki67在甲状腺乳头状癌中的表达[J].黑龙江医学,2005,29(3):168-169. 被引量:4
  • 2蔡绥勍,王海军,郑敏,陈丽荣,姚丽芳.皮肤鳞状细胞癌STAT3和MAPK磷酸化及cyclinD1蛋白表达的意义[J].中国皮肤性病学杂志,2005,19(8):449-451. 被引量:4
  • 3李晓明.血管内皮细胞生长因子及其受体与肿瘤血管形成[J].国外医学(肿瘤学分册),1997,24(1):11-13. 被引量:54
  • 4Hegedüs L.Clinical Practice:the Thyroid Nodule[J].N Engl J Med,2004,351(17):1764-1771.
  • 5Shaha A R.Controversies in the Management of Thyroid Nodule[J].Laryngoscope,2000,110(2 Pt l):183-193.
  • 6Hay I D,Thompson G B,Grant C S,et al.Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades(1940-1999):Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients[J].World J Surg,2002,26(8):879-885.
  • 7Passler C,Scheuba C,Prager G,et al.Prognostic Factors of Papillary and Follicular Thyroid Cancer:Differences in an Iodine-Replete Endemic Goiter Region[J].Endocr Relat Cancer,2004,11(1):131-139.
  • 8Maeda K,Chung Y S,Ogawa Y,et al.Prognostic Value of Vascular Endothelial Growth Factor Expression in Gastric Carcinoma[J].Cancer,1996,77(5):858-863.
  • 9Yamamoto S,Konishi I,Mandai M,et al.Expression of Vascular Endothelial Growth Factor (VEGF) in Epithelial Ovarian Neoplasms:Correlation with Clinicopathology and Patient Survival,and Analysis of Serum VEGF Levels[J].Br J Cancer,1997,76(9):1221-1227.
  • 10Yuan A,Yu C J,Chen W J,et al.Correlation of Total VEGF mRNA and Protein Expression with Histologic Type,Tumor Angiogenesis,Patient Survival and Timing of Relapse in Non-small-cell Lung Cancer[J].Int J Cancer,2000,89(6):475-483.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部